cyc 202 has been researched along with leflunomide in 5 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (leflunomide) | Trials (leflunomide) | Recent Studies (post-2010) (leflunomide) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 1,725 | 173 | 659 |
| Protein | Taxonomy | cyc 202 (IC50) | leflunomide (IC50) |
|---|---|---|---|
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | 0.03 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.5 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 4.63 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 4.63 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.884 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | 5.4 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Cory, AH; Cory, JG; Edwards, CC; Hall, JG | 1 |
5 other study(ies) available for cyc 202 and leflunomide
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Inhibitors of diverse metabolic steps cause increased apoptosis in deoxyadenosine-resistant mouse leukemia L1210 cells that lack p53 expression: convergence at caspase-3 activation.
Topics: Androstadienes; Animals; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyrates; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Coloring Agents; Deoxyadenosines; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Genistein; Isoxazoles; Leflunomide; Mice; Models, Biological; Purines; RNA, Messenger; Roscovitine; Sesquiterpenes; Time Factors; Tumor Suppressor Protein p53; Wortmannin | 2003 |